|Bid||13.08 x 900|
|Ask||13.19 x 800|
|Day's Range||12.38 - 13.29|
|52 Week Range||8.88 - 18.25|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The 700+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the second quarter, which unveil their equity positions as of June 28. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund portfolios. Our extensive […]
T2 Biosystems and Replimune Group have spurted higher in the last couple weeks, with the former doubling in value on encouraging news.
It's easy to match the overall market return by buying an index fund. But if you buy individual stocks, you can do...
Small-cap biotech Replimune's lead asset RP1, a genetically modified herpes virus that serves to boost the virus' ability to kill tumor cells, is likely to be successful, Driscoll said in the Wednesday initiation note.
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders Read More...
The elite funds run by legendary investors such as Dan Loeb and David Tepper make hundreds of millions of dollars for themselves and their investors by spending enormous resources doing research on small cap stocks that big investment banks don’t follow. Because of their pay structures, they have strong incentive to do the research necessary […]